{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"EORTC QLQ-C30 is a 30-item patient-reported questionnaire. 28 of the 30 items are measured on a 1-4 scale (1=not at all; 4=very much) with the remaining two items (overall health and overall quality of life) scored on a 1-7 numeric analogue scale (1=very poor; 7=excellent). The recall period for the EORTC QLQ-C30 is one week.\n\nChanges from baseline will be statistically tested using paired t-tests, and standardized response means (mean of the change from baseline scores at a given cycle, divided by the standard deviation of the change scores) will be interpreted (after applying Middel's (2002) adjustment) using Cohen's (1988) cut-offs: \\<0.20 = trivial; 0.20-\\<0.50 = small; 0.50-\\<0.80 = moderate; and \\>=/0.80 = large. Correlation between outcomes will employ Pearson and/or Spearman correlations at individual time points.","groups":[{"description":"Participants received avelumab IV over 60 minutes every 14 days for a total of 10 courses in the absence of disease progression or unacceptable toxicity. Beginning 29 days after the first dose of avelumab, participants received 35 mg/m\\^2/day cisplatin IV starting on day 1 of courses 3-5 for up to 6 weeks in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Avelumab and Cisplatin IV"}],"populationDescription":"All patients who were registered, treated, and completed the EORTC QLQ assessment at baseline and post-therapy were included in this analysis","reportingStatus":"POSTED","timeFrame":"Baseline to 12 months","title":"Patient-reported Outcomes (European Organization for Research and Treatment of Cancer [EORTC] Quality of Life Questionnaire [QLQ]-30","type":"SECONDARY"}